In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone

Toxicological Sciences

Volumn 103, Issue 2, 2008, Pages 335-345

  Dykens, James A ^a   Jamieson, Joseph D ^b   Marroquin, Lisa D ^b   Nadanaciva, Sashi ^c   Xu, Jinghai J ^d   Dunn, Margaret C ^d   Smith, Arthur R ^d   Will, Yvonne ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

^c MitoSciences Inc   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Buspirone; Drug toxicity; Hepatotoxicity; Mitochondria; Nefazodone; Trazodone

Indexed keywords

ADENOSINE TRIPHOSPHATE; BUSPIRONE; CYTOCHROME C OXIDASE; CYTOCHROME P450 3A4; GLUTATHIONE; NEFAZODONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); TRAZODONE; UBIQUINOL CYTOCHROME C REDUCTASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; DRUG MARKETING; DRUG WITHDRAWAL; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; ISOLATED LIVER; LIVER CELL; LIVER MITOCHONDRION; LIVER TOXICITY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; UNITED STATES;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUSPIRONE; CELL LINE; CELL RESPIRATION; CELL SURVIVAL; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HUMANS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; METABOLIC NETWORKS AND PATHWAYS; MITOCHONDRIA, LIVER; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; RATS; RATS, SPRAGUE-DAWLEY; TRAZODONE; TRIAZOLES;

RATTUS;

EID: 43349090542     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfn056     Document Type: Article

References (39)

1. Alderman, C. P. (1999). Possible interaction between nefazodone and pravastatin. Ann. Pharmacother 33, 871.
2. Aranda-Michel, J., Koehler, A., Bejerano, P. A., Poulos, J. E., Luxon, B. A., Khan, C. M., Ee, L. C., Balistreri, W. F., and Weber, F. L. (1999). Nefazodone-induced liver failure: Report of three cases. Ann. Intern. Med. 130, 285-288.
3. Barbhaiya, R. H., Marathe, P. H., Greene, D. S., Mayol, R. F., Shukla, U. A., Gammans, R. R., Pittman, K. A., and Robinson, D. (1995). Safety, tolerance and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: A double-blind phase I study. J. Clin. Pharmacol. 35, 974-984.
4. Beck, P. L., Bridges, R. J., Demetrick, D. J., Kelly, J. K., and Lee, S. S. (1993). Chronic active hepatitis associated with trazodone therapy. Ann. Intern. Med. 118, 791-792.
5. Benazzi, F. (1997). Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy. J. Psychopharmacol. 11, 190.
6. Boelsterli, U. A. (2003). Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol 192, 307-322.
7. Brown, G. C., and Borutaite, V. (2007). Nitric oxide and mitochondrial respiration in the heart. Cardiovasc. Res. 75, 283-290.
8. Caccia, S. (2007). N-dealkylation of arylpiperazine derivatives: Disposition and metabolism of the 1-aryl-piperazines formed. Curr. Drug Metab 8, 612-622.
9. Chan, K., Truong, D., Shangari, N., and O'Brien, P. J. (2005). Drug-induced mitochondrial toxicity. Expert Opin. Drug Metab. Toxicol. 1, 655-666.
10. Choi, S. (2003). Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ. 169, 1187.
11. Chu, A. G., Gunsolly, B. L., Summers, R. W., Alexander, B., McChesney, C., and Tanna, V. L. (1983). Trazodone and liver toxicity. Ann. Intern. Med. 99, 128-129.
12. DeSanty, K. P., and Amabile, C. M. (2007). Antidepressant-induced liver injury. Ann. Pharmacother. 41(7), 1201-1211.
13. +: Implications for neurodegeneration. J. Neurochem. 63, 584-591.
14. Dykens, J. A., Marroquin, L. D., and Will, Y. (2007). Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev. Mol. Diagn. 7, 161-175.
15. Dykens, J. A., and Will, Y. (2007). The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 12, 777-785.
16. Eison, A. S., Eison, M. S., Torrente, J. R., Wright, R. N., and Yocca, F. D. (1990). Nefazodone: Preclinical pharmacology of a new antidepressant. Psychopharmacol. Bull. 26, 311-315.
17. Eloubeidi, M. A., Gaede, J. T., and Swaim, M. W. (2000). Reversible nefazodone-induced liver failure. Dig. Dis. Sci. 45, 1036-1038.
18. Fernandes, N. F., Martin, R. R., and Schnenker, S. (2000). Trazodone-induced hepatotoxicity: A case report with comments on drug-induced hepatotoxicity. Am. J. Gastroenterol. 95, 532-535.
19. Hull, M., Jones, R., and Bendall, M. (1994). Fatal hepatic necrosis associated with trazodone and neuroleptic drugs. BMJ 309, 378.
20. Hynes, J., Marroquin, L. D., Ogurtsov, V. I., Christiansen, K. N., Stevens, G. J., Papkovsky, D. B., and Will, Y. (2006). Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. Toxicol. Sci. 92, 186-200.
21. Karnik, N. S., and Maldonado, J. R. (2005). Antidepressant and statin interactions: A review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics 46, 565-568.
22. Kostrubsky, S. E., Strom, S. C., Kalgutkar, A. S., Kulkarni, S., Atherton, J., Mireles, R., Feng, B., Kubik, R., Hanson, J., Urda, E., et al. (2006). Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90, 451-459.
23. Kostrubsky, V. E., Vore, M., Kindt, E., Burliegh, J., Rogers, K., Peter, G., Altrogge, D., and Sinz, M. W. (2001). The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats. Drug Metab. Dispos. 29, 1561-1566.
24. Longstreth, G. F., and Hershman, J. (1985). Trazodone-induced hepatotoxicity and leukonychia. J. Am. Acad. Dermatol. 13, 149-150.
25. Lucena, M. I., Carvajal, A., Andrade, R. J., and Velasco, A. (2003). Antidepressant-induced hepatoxicity. Expert Opin. 2, 249-262.
26. Marroquin, L. D., Hynes, J., Dykens, J. A., Jamieson, J. D., and Will, Y. (2007). Circumventing the crabtree effect: Replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97, 539-547.
27. Nadanaciva, S., Bernal, A., Aggeler, R., Capaldi, R., and Will, Y. (2007a). Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol. In Vitro 21, 902-911.
28. Nadanaciva, S., Dykens, J. A., Bernal, A., Capaldi, R. A., and Will, Y. (2007b). Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol. Appl. Pharmacol. 38, 33-42.
29. Nilsen, O. G., and Dale, O. (1992). Single dose pharmacokinetics of trazodone in healthy subjects. Pharmacol. Toxicol. 71, 150-153.
30. Ong, M. M., Latchoumycandane, C., and Boelsterli, U. A. (2007). Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol. Sci. 97, 205-213.
31. Sheikh, K. H., and Nies, A. S. (1983). Trazodone and intrahepatic cholestasis. Ann. Intern. Med. 99, 572.
32. Skar, A., and Andheria, M. (2001). A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. J. Clin. Pharmacol. 41, 886-894.
33. Smith, A. L. (1967). Preparation, properties, and conditions for assay of mitochondria: Slaughterhouse material, small-scale. Methods Enzymol. 10, 81-86.
34. Szewczyk, A., and Wojtczak, L. (2002). Mitochondria as a pharmacological target. Pharmacol. Rev. 54, 101-127.
35. Taylor, D. P., Carter, R. B., Eison, A. S., Mullins, U. L., Smith, H. L., Torrente, J. R., Wright, R. N., and Yocca, F. D. (1995). Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J. Clin. Psychiatry 56, 3-11.
36. Wallace, K. B., and Starkov, A. (2000). Mitochondrial targets of drug toxicity. Annu. Rev. Pharmacol. Toxicol. 40, 353-388.
37. Westwood, F. R., Bigley, A., Randall, K., Marsden, A. M., and Scott, R. C. (2005). Statin-induced muscle necrosis in the rat: Distribution, development, and fibre selectivity. Toxicol. Pathol. 33, 246-257.
38. Wilkening, S., Stahl, F., and Bader, A. (2003). Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their bio-transformation properties. Drug Metab. Dispos. 31, 1035-1042.
39. Will, Y., Hynes, J., Ogurtsov, V. I., and Papkovsky, D. B. (2006). Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. Nat. Protoc. 1, 2563-2572.